TSE:4516Pharmaceuticals
Nippon Shinyaku (TSE:4516) Secures Tadekinig Alfa US Rights, Is The Valuation Gap Justified?
Nippon Shinyaku (TSE:4516) has exercised its option with AB2 BIO to secure exclusive United States commercialization rights for Tadekinig alfa, a rare disease therapy with multiple special regulatory designations.
See our latest analysis for Nippon Shinyaku.
The Tadekinig alfa agreement comes as Nippon Shinyaku’s recent 1-day share price return of 1.9% contrasts with a year to date share price decline of 36.05%. The 1-year total shareholder return of 12.02% sits against a 5-year total...